This review highlights emerging therapies and techniques in phase II clinical trials for pulmonary arterial hypertension, targeting novel pathobiological mechanisms.
Answers are grounded in this paper and cite their sources.
Phase II PAH therapies targeting novel mechanisms should not yet enter routine care; leaves open their ability to improve outcomes in future trials.
While there have been advances in the field of pulmonary arterial hypertension (PAH), disease management remains suboptimal for many patients. The development of novel treatments and strategies can provide opportunities to target other mechanisms that play a role in the complex pathobiology of PAH outside of the three main pathophysiological pathways. In this review, we highlight some of the potential PAH therapies or techniques that are being, or have been, investigated in phase II clinical trials. This review also discusses potential points for consideration in the development of novel therapies that target putative disease mediators or modifiers.
No takes yet. Share an insight, caveat, or question.
Simonneau et al. (2016) conducted a review in Pulmonary arterial hypertension (PAH). Novel PAH therapies (targeting inflammation/immunity, mitochondrial dysfunction, BMPR2 signalling, iron deficiency, and pulmonary artery denervation) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: